Feb 06, 2017
Newcastle upon Tyne, UK – [February 2, 2017] – QuantuMDx Group announced an assay co-development and commercialization agreement with The Global Good Fund, managed by Intellectual Ventures, to develop a rapid, low-cost and mobile diagnostic test for the detection of human papillomavirus (HPV), the leading cause of cervical and other genital cancers.
Jan 24, 2017
Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits.
Jan 03, 2017
Mologic is pleased to announce that we are in receipt of a grant from the Bill & Melinda Gates Foundation to establish the CARD, a new technology centre within Mologic, whose objective is to create a step-change in simple, rapid diagnostic test technology for the detection of protein biomarkers at the point-of care.